Primary hyperparathyroidism: Pathophysiology and impact on bone

CMAJ. Canadian Medical Association Journal

Volumn 163, Issue 2, 2000, Pages 184-187

  Khan, A ^a   Bilezikian, J ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE ATROPHY; BONE DENSITY; CALCIUM HOMEOSTASIS; CANCELLOUS BONE; ESTROGEN THERAPY; HUMAN; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; REVIEW; SUBSTITUTION THERAPY;

EID: 0034713771     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Primary hyperparathyroidism: Diagnosis and management - A review
2. Epidemiology of primary hyperparathyroidism
3. The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992
4. Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management
5. Prevalence of hypercalcemia in a health survey: A 14-year follow-up study of serum calcium values
6. Circulating levels of interleukin-6 and tumor necrosis factor-alpha - A clinical research center study
7. 2+-sensing receptor from bovine parathyroid
8. The extracellular calcium-sensing receptor: Its role in health and disease
9. Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism
10. 2+-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism
11. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism
12. Positional cloning of the gene for multiple endocrine neoplasia-type I
13. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
14. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II
15. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton
16. Increased fracture risk in hypercalcemia. Bone mineral content measured in hyperparathyroidism
17. Skeletal disease in primary hyperparathyroidism
18. Longitudinal changes in bone mineral density and bone turnover in post-menopausal women with primary hyperparathyroidism
19. Total and regional bone mineral content in primary hyperparathyroidism: Sex differences
20. Serum levels of intact parathyroid hormone and alkaline phosphatase correlate with cortical and trabecular bone loss in primary hyperparathyroidism
21. Accelerated bone loss in post-menopausal women with primary hyperparathyroidism
22. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone mineral density at the hip and spine in post-menopausal osteoporosis
23. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery
24. Vertebral osteopenia: A new indication of surgery in primary hyperparathyroidism
25. Risk of age-related fractures in patients with primary hyperparathyroidism
26. The risk of hip fractures in patients with primary hyperparathyroidism: A population-based cohort study with a follow-up of 19 years
27. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures
28. Fracture incidence in postmenopausal women with primary hyperparathyroidism
29. Back pain and vertebral crush fractures: An unemphasized mode of presentation for primary hyperparathyroidism
30. What is the clinical significance of bone loss in primary parathyroidism?
31. Consensus development conference statement
32. The effect of hormone replacement therapy on bone mineral density in post-menopansal women with primary hyperparathyroidism. A randomized controlled trial
33. Ethynyl estradiol and norethindrone in the treatment of primary hyperparathyruidism in post-menopausal women
34. Conjugated estrogen in the treatment of post-menopausal women with hyperparathyroidism
35. Effects of dichloromethytene diphosphonate on serum and urinary calcium in primary hyperparathyroidism
36. Clodronate in the medical management of hyperparathyruidism
37. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate
38. Regulation of calcium-parathyroid hormone feedback in primary hyperthyroidism: Effects of bisphosphonate treatment
39. Treatment of hyperparathyroidism with etidronate disodium
40. Alendronate in the treatment of primary hyperparathyroidism-related osteoporosis [abstract]
41. Alendronate therapy of primary hyperparathyroidism [abstract]
42. Calcimimetics: Structurally and mechanistically novel compounds that inhibit hormone secretion from parathyroid cells [abstract]
43. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism